Daniel Fletcher
microRNA expression in acute myeloid leukaemia: New targets for therapy?
Fletcher, Daniel; Brown, Elliott; Javadala, Julliah; Uysal-Onganer, Pinar; Guinn, Barbara
Authors
Elliott Brown
Julliah Javadala
Pinar Uysal-Onganer
Dr Barbara Guinn B.Guinn@hull.ac.uk
Reader in Biomedical Sciences
Abstract
Recent studies have shown that short non-coding RNAs, known as microRNAs (miRNAs) and their dysregulation, are implicated in the pathogenesis of acute myeloid leukaemia (AML). This is due to their role in the control of gene expression in a variety of molecular pathways. Therapies involving miRNA suppression and replacement have been developed. The normalisation of expression and the subsequent impact on AML cells have been investigated for some miRNAs, demonstrating their potential to act as therapeutic targets. Focussing on miRs with therapeutic potential, we have reviewed those that have a significant impact on the aberrant biological processes associated with AML, and crucially, impact leukaemic stem cell survival. We describe six miRNAs in preclinical trials (miR-21, miR-29b, miR-126, miR-181a, miR-223 and miR-196b) and two miRNAs that are in clinical trials (miR-29 and miR-155). However none have been used to treat AML patients and greater efforts are needed to develop miRNA therapies that could benefit AML patients in the future.
Citation
Fletcher, D., Brown, E., Javadala, J., Uysal-Onganer, P., & Guinn, B. (2022). microRNA expression in acute myeloid leukaemia: New targets for therapy?. eJHaem, 3(3), 596-608. https://doi.org/10.1002/jha2.441
Journal Article Type | Review |
---|---|
Acceptance Date | Mar 31, 2022 |
Online Publication Date | Apr 26, 2022 |
Publication Date | 2022-08 |
Deposit Date | Nov 14, 2022 |
Publicly Available Date | Nov 14, 2022 |
Journal | eJHaem |
Print ISSN | 2688-6146 |
Publisher | John Wiley and Sons |
Peer Reviewed | Peer Reviewed |
Volume | 3 |
Issue | 3 |
Pages | 596-608 |
DOI | https://doi.org/10.1002/jha2.441 |
Keywords | Acute myeloid leukaemia (AML); microRNA; miRNA; Stemness; Therapy |
Public URL | https://hull-repository.worktribe.com/output/4010715 |
Files
Published article
(1.3 Mb)
PDF
Publisher Licence URL
http://creativecommons.org/licenses/by/4.0
Copyright Statement
© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
You might also like
Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia
(2024)
Journal Article
Can tumour antigens act as biomarkers for the early detection of non-small cell lung cancer?
(2024)
Journal Article
Survivin’ acute myeloid leukaemia—a personalised target for inv(16) patients
(2021)
Journal Article
Downloadable Citations
About Repository@Hull
Administrator e-mail: repository@hull.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search